UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease

Naunyn-Schmiedeberg's archives of pharmacology, 2021-12, Vol.394 (12), p.2363-2379

2021

Volltextzugriff (PDF)

6‑Alkoxy-5-aryl-3-pyridinecarboxamides, a New Series of Bioavailable Cannabinoid Receptor Type 1 (CB1) Antagonists Including Peripherally Selective Compounds

Journal of medicinal chemistry, 2013-12, Vol.56 (24), p.9874-9896

2013

Volltextzugriff (PDF)

Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels

Journal of hypertension, 2010-08, Vol.28 (8), p.1676-1686

2010

Volltextzugriff (PDF)

The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective

International journal of molecular sciences, 2018-06, Vol.19 (6), p.1712

2018

Volltextzugriff (PDF)

Urinary miRNA Profiles in Chronic Kidney Injury-Benefits of Extracellular Vesicle Enrichment and miRNAs as Potential Biomarkers for Renal Fibrosis, Glomerular Injury, and Endothelial Dysfunction

Toxicological sciences, 2022-04, Vol.187 (1), p.35-50

2022

Volltextzugriff (PDF)

Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation

Circulation (New York, N.Y.), 2000-07, Vol.102 (1), p.104-112

2000

Volltextzugriff (PDF)

Therapy with a Selective Cannabinoid Receptor Type 2 Agonist Limits Albuminuria and Renal Injury in Mice with Type 2 Diabetic Nephropathy

Nephron (2015), 2016-01, Vol.132 (1), p.59-69

2016

Volltextzugriff (PDF)

Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes

Bioorganic & medicinal chemistry letters, 2009-05, Vol.19 (9), p.2468-2473

2009

Volltextzugriff (PDF)

Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome

Cardiovascular diabetology, 2011-01, Vol.10 (1), p.7-7

2011

Volltextzugriff (PDF)

Differential efficacy of L- and T-type calcium channel blockers in preventing tachycardia-induced atrial remodeling in dogs

Cardiovascular research, 2001-03, Vol.49 (4), p.762-770

2001

Volltextzugriff (PDF)

Effects of pioglitazone and fenofibrate co-administration on bone biomechanics and histomorphometry in ovariectomized rats

Journal of bone and mineral metabolism, 2015-11, Vol.33 (6), p.625-641

2015

Volltextzugriff (PDF)

Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney

British journal of pharmacology, 2022-06, Vol.179 (11), p.2476-2489

2022

Volltextzugriff (PDF)

Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats

Journal of endocrinology, 2012-02, Vol.212 (2), p.179-186

2012

Volltextzugriff (PDF)

Benzodioxoles: Novel Cannabinoid-1 Receptor Inverse Agonists for the Treatment of Obesity

Journal of medicinal chemistry, 2008-04, Vol.51 (7), p.2115-2127

2008

Volltextzugriff (PDF)

The T-type Ca(2+) channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling in dogs

Circulation (New York, N.Y.), 1999-11, Vol.100 (21), p.2191-2197

1999

Volltextzugriff (PDF)

Responses in Blood Pressure and Kidney Function to Soluble Guanylyl Cyclase Stimulation or Activation in Normal and Diabetic Rats

Nephron (2015), 2023-05, Vol.147 (5), p.281-300

2023

Volltextzugriff (PDF)

5-HT2C Receptor Agonists for the Treatment of Obesity. Biological and Chemical Adventures

Chimia, 2004-09, Vol.58 (9), p.613

2004

Volltextzugriff (PDF)

Pharmacological properties of Ca v 3.2, a low voltage-activated Ca 2+ channel cloned from human heart

Naunyn-Schmiedeberg's archives of pharmacology, 2000-05, Vol.361 (6), p.590-599

2000

Volltextzugriff (PDF)

Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs

Cardiovascular research, 2001-04, Vol.50 (1), p.85-96

2001

Volltextzugriff (PDF)

Design and Biological Evaluation of Novel, Balanced Dual PPARα/γ Agonists

ChemMedChem, 2009-06, Vol.4 (6), p.951-956

2009

Volltextzugriff (PDF)

The sGC Activator Runcaciguat Has Kidney Protective Effects and Prevents a Decline of Kidney Function in ZSF1 Rats

International journal of molecular sciences, 2023-09, Vol.24 (17), p.13226

2023

Volltextzugriff (PDF)

Nitric oxide regulates the calcium current in isolated human atrial myocytes

The Journal of clinical investigation, 1995-02, Vol.95 (2), p.794-802

1995

Volltextzugriff (PDF)

Quantitative body composition analysis in awake mice and rats by magnetic resonance relaxometry

Obesity (Silver Spring, Md.), 2004-10, Vol.12 (10), p.1604-1615

2004

Volltextzugriff (PDF)

cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes

The Journal of clinical investigation, 1997-06, Vol.99 (11), p.2710-2718

1997

Volltextzugriff (PDF)

Animal Models of Diabetic Macrovascular Complications: Key Players in the Development of New Therapeutic Approaches

Journal of Diabetes Research, 2015-01, Vol.2015 (2015), p.1-14

2015

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(51)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease

6‑Alkoxy-5-aryl-3-pyridinecarboxamides, a New Series of Bioavailable Cannabinoid Receptor Type 1 (CB1) Antagonists Including Peripherally Selective Compounds

Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels

The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective

Urinary miRNA Profiles in Chronic Kidney Injury-Benefits of Extracellular Vesicle Enrichment and miRNAs as Potential Biomarkers for Renal Fibrosis, Glomerular Injury, and Endothelial Dysfunction

Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation

Therapy with a Selective Cannabinoid Receptor Type 2 Agonist Limits Albuminuria and Renal Injury in Mice with Type 2 Diabetic Nephropathy

Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes

Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome

Differential efficacy of L- and T-type calcium channel blockers in preventing tachycardia-induced atrial remodeling in dogs

Effects of pioglitazone and fenofibrate co-administration on bone biomechanics and histomorphometry in ovariectomized rats

Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney

Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats

Benzodioxoles: Novel Cannabinoid-1 Receptor Inverse Agonists for the Treatment of Obesity

The T-type Ca(2+) channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling in dogs

Responses in Blood Pressure and Kidney Function to Soluble Guanylyl Cyclase Stimulation or Activation in Normal and Diabetic Rats

5-HT2C Receptor Agonists for the Treatment of Obesity. Biological and Chemical Adventures

Pharmacological properties of Ca v 3.2, a low voltage-activated Ca 2+ channel cloned from human heart

Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs

Design and Biological Evaluation of Novel, Balanced Dual PPARα/γ Agonists

The sGC Activator Runcaciguat Has Kidney Protective Effects and Prevents a Decline of Kidney Function in ZSF1 Rats

Nitric oxide regulates the calcium current in isolated human atrial myocytes

Quantitative body composition analysis in awake mice and rats by magnetic resonance relaxometry

cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes

Animal Models of Diabetic Macrovascular Complications: Key Players in the Development of New Therapeutic Approaches

Suchergebnisse filtern